Emerging role of the immunotherapy in treatment of breast cancer | ||||
| SVU-International Journal of Medical Sciences | ||||
| Article 19, Volume 4, Issue 2, August 2021, Page 172-176 PDF (328.29 K) | ||||
| Document Type: Reviews Articles. | ||||
| DOI: 10.21608/svuijm.2020.47814.1018 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nagwa Abd El-Sadek Ahmed  ; Maisa Hashem Mohammed
| ||||
| Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt | ||||
| Abstract | ||||
| Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated with the worst prognosis and is resistantto the conventional therapeutic agents. Recently, the immunotherapy has achieved satisfactory results in the treatment of breast cancer in general and in TNBC in particular. The immune checkpoints are targeted in many clinical trials. The checkpoint inhibitors results in advances in treatment of breast cancer, especially refractory molecular subtypes. This review is aimedto highlight the current knowledge on the immunotherapy and the advances in its implications in treatment of breast cancer with emphasis on newly approved therapeutic approaches in this field. Conclusion: The immunotherapy is considered as an emerging therapeutic strategy for treatment of breast cancer, particularly TNBC.Several clinical trials focusing on the potential role of immunotherapy in breast cancer are still under research. | ||||
| Keywords | ||||
| TNBC; immunotherapy; Programmed Death 1; Programmed Death Ligand 1 | ||||
|
Statistics Article View: 231 PDF Download: 174 |
||||
